ClinicalTrials.gg
CompletedNCT05546359Updated Jun 25, 2025

Study of Intravenous Amisulpride for Prophylaxis of Post-operative Nausea and Vomiting (PONV) in Pediatric Patients

A Phase 2/3 interventional study of Amisulpride Injection and Dexamethasone in Nausea and Vomiting, Postoperative, sponsored by Acacia Pharma Ltd. Completed at 14 sites in 4 countries. Open to participants aged 2 Months to 17 Years. Per ClinicalTrials.gov, last updated 2025-06-25.

Sponsored by Acacia Pharma Ltd · Phase 2/3, Interventional, and Prevention

How we know

From the registry’s dates

  • Primary completion was Jun 2025, 1 year 5 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
453
Allocation
Randomized
Ages
2 Months to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies testing amisulpride in Postoperative Nausea and Vomiting — 2 open to participants now, 2 under way, none of them phase 3. Amisulpride · Postoperative Nausea and Vomiting.

Enrollment
6th of 11
453 · median 453
Started
2024
the only one that year
Phase 2/3
Only one
of the 11
Registered
8th of 11
by date
Lead sponsor
8 of 11
Acacia Pharma Ltd

Among the 11 studies testing amisulpride in Postoperative Nausea and Vomiting, this one is the 6th largest by enrollment, is the only one that started in 2024, is the only one in phase 2/3, and was the 8th registered.

Postoperative Nausea and Vomiting

638 studies on the registry are indexed under Postoperative Nausea and Vomiting; 110 are open to participants now.

Browse Postoperative Nausea and Vomiting studies →

Open to participants now

2 of the 11 studies testing amisulpride in Postoperative Nausea and Vomiting are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About amisulpride

Amisulpride: first FDA approval 2020 (BARHEMSYS). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 66 Postoperative Nausea and Vomiting studies recruiting now, 22 (33%) set no upper age limit and 38 (58%) stop at 75 or younger; 15 take children under 18; 11 take healthy volunteers.

This study: 2 Months to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies testing amisulpride in Postoperative Nausea and Vomiting, or all of them as a file.
02

Study summary

Randomized, double-blind, pediatric trial of amisulpride for prophylaxis of post operative nausea and vomiting

Read the detailed description

Randomized, double-blind, Phase 2/3 study of IV amisulpride as prevention of post-operative nausea and vomiting in pediatric patients

03

Conditions studied

  • Nausea and Vomiting, Postoperative
04

Who can participate

Ages eligible
2 Months to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female patients aged from full-term birth to 17 years of age
  2. Signed form and/or assent and willingness of patient and parents to participate in the trial
  3. Patients undergoing non-emergency surgery, preferentially eye surgery, adenotonsillectomy or otoplasty, under general anesthesia (other than total intravenous anesthesia with propofol) expected to last at least 30 minutes from induction of anesthesia to removal of Endotracheal tube (ETT) or Laryngeal mask airway (LMA)
  4. (ASA) risk score I-III
  5. For females of : ability and willingness to use a highly effective form of (as defined in ICH M3 guidance, e.g., true (not periodic) abstinence from sexual intercourse, surgical sterilization (of subject or partner), combined oral contraceptive pill, or any other method or combination of methods with a failure rate generally considered to be \<1% per year) between the date of screening and at least 48 hours after administration of study drug.

Exclusion criteria

Exclusion Criteria:

  1. Patients scheduled to undergo transplant or Central Nervous System (CNS) surgery
  2. Patients scheduled to receive only a local anesthetic and/or regional neuraxial (intrathecal or epidural) block (without general anesthesia) or to receive general anesthesia involving total intravenous anesthesia (TIVA) with propofol
  3. Patients who, in the opinion of the Investigator, are expected to remain ventilated for a significant period after surgery
  4. Patients who are expected to need a naso- or orogastric tube in situ after surgery is completed
  5. Patients who are expected to receive systemic pre/peri-operative therapy other than as anti-emetic prophylaxis
  6. Patients receiving amisulpride for any indication within the 2 weeks prior to randomization
  7. Patients known to be allergic to amisulpride or any of the of amisulpride drug product; or to dexamethasone or ondansetron
  8. Patients with a significant ongoing history of vestibular disease or dizziness
  9. Patients being treated with regular anti-emetic therapy (dosed at least three times per week), which is still ongoing less than 1 week prior to screening
  10. Patients being treated with levodopa, or any other dopamine D2-agonist
  11. Patients who are pregnant or breast feeding
  12. Patients with congenital long (QT) syndrome
  13. Patients with a tumor of the anterior pituitary
  14. Patients who have received emetogenic anti-cancer chemotherapy in the previous 4 weeks
  15. Any other concurrent disease or illness that, in the opinion of the investigator makes the patient unsuitable for the study
  16. Patients who have previously participated in this study or who have participated in another interventional clinical study involving pharmacological therapy within the previous 28 days (or longer exclusion period, if required by national or local regulations)
  17. Where local laws/regulations require: patients under legal protection
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
453 participants (actual)

Study arms

  • Experimental
    Stage 1 - Group 1: IV amisulpride 0.035 mg/kg + IV dexamethasone

    Stage 1 - Group 1: IV amisulpride 0.035 mg/kg + IV dexamethasone

    Drug: Amisulpride Injection · Drug: Dexamethasone

  • Experimental
    Stage 1 - Group 2: IV amisulpride 0.07 mg/kg + IV dexamethasone

    Stage 1 - Group 2: IV amisulpride 0.07 mg/kg + IV dexamethasone

    Drug: Amisulpride Injection · Drug: Dexamethasone

Interventions

06

What researchers measure

Primary outcomes

  1. Evaluate Complete Response

    Defined as no vomiting/retching (absence of PONV) and no use of anti-emetic rescue medication, during the first 24 hours after completion of surgery. Subjects will be questioned and assessed.

    Time frame: 1 Day

Secondary outcomes

  1. Occurrence of post-operative vomiting/retching

    Subjects considered able to understand and provide a meaningful response should be asked if they have nausea ("feel sick" or other equivalent words) at the following times after completion of surgery (wound closure), unless an episode of PONV or discharge of the subject from the site has already occurred prior to the time point: 1 hour, 2 hours, 6 hours and 24 hours or when they first vomit, retch or receive rescue medication. In subjects aged ≥ 6 years, at the above time points and for any spontaneously reported nausea episode, nausea severity should be scored using the validated 6-point Baxter Retching Faces (BARF) scale.

    Time frame: 1 Day

  2. Use of rescue medication

    Document use of rescue medication.

    Time frame: 1 Day

  3. Occurrence and severity of post-operative nausea

    An episode of nausea should be recorded any time that a subject spontaneously complains of nausea (including a request for rescue medication due to nausea). Subjects considered able to understand and provide a meaningful response should be asked if they have nausea ("feel sick" or other equivalent words) at the following times after completion of surgery (wound closure), unless an episode of PONV or discharge of the subject from the site has already occurred prior to the time point: 1 hour, 2 hours, 6 hours and 24 hours or when they first vomit, retch or receive rescue medication. In subjects aged ≥ 6 years, at the above time points and for any spontaneously reported nausea episode, nausea severity should be scored using the validated 6-point Baxter Retching Faces (BARF) scale.

    Time frame: 1 Day

  4. Time to emergence of PONV

    Observe for, question and document emergence of vomiting/retching and nausea. In subjects aged ≥ 6 years, at specified time points and for any spontaneously reported nausea episode, nausea severity should be scored using the validated 6-point Baxter Retching Faces (BARF) scale.

    Time frame: 1 Day

  5. Time to emergence of vomiting/retching, significant nausea, and rescue medication, individually

    Observe for emergence of vomiting/retching, determine significance of nausea, and note rescue medication, individually.

    Time frame: 1 Day

  6. Different variables during different time ranges after the end of surgery (0-2 h, 2-6 h and 6-24 h)

    Subjects considered able to understand and provide a meaningful response should be asked if they have nausea ("feel sick" or other equivalent words) at the following times after completion of surgery (wound closure), unless an episode of PONV or discharge of the subject from the site has already occurred prior to the time point: 1 hour, 2 hours, 6 hours and 24 hours or when they first vomit, retch or receive rescue medication. In subjects aged ≥ 6 years, at the above time points and for any spontaneously reported nausea episode, nausea severity should be scored using the validated 6-point Baxter Retching Faces (BARF) scale.

    Time frame: 1 Day

  7. The above variables in the sub-groups of patients who did and did not receive opioid analgesia

    Concomitant medications will be reviewed.

    Time frame: 1 Day

  8. Safety: The nature and frequency of adverse events and laboratory and electrocardiography (ECG) abnormalities

    Adverse events, laboratory and ECG abnormalities will be noted. Blood samples should be drawn at screening (unless recent pre-existing results are available) and again post-operatively, as soon as practically possible after the patient's entry to the post-anesthesia care unit, recovery room or equivalent, and in any event within 1 hour after the end of surgery. Twelve-lead ECGs will be collected at screening. An ECG already taken as part of medical care within the period of 2 weeks prior to screening may be used to determine eligibility and to provide baseline ECG data. In the peri-/post-operative period, continuous Holter monitoring of the ECG will be performed, from at least 10 minutes prior until at least 2 hours after the start of administration of amisulpride study medication.

    Time frame: 7 Days

  9. Key pharmacokinetics parameter - Peak Plasma Concentration

    Plasma samples will be drawn as required at specified timepoints to determine the PK profile of peak plasma concentration of amisulpride in subjects.

    Time frame: 1 Day

  10. Key pharmacokinetics parameter - Total Exposure

    Plasma samples will be drawn as required at specified timepoints to determine the PK profile of total exposure of amisulpride in subjects.

    Time frame: 1 Day

07

Study locations

14 sites
  • Helen Keller Hospital
    Sheffield, Alabama 35660, United States
  • Emory Healthcare - Emory University Hospital
    Atlanta, Georgia 30322, United States
  • University of Minnesota Masonic Children's Hospital
    Minneapolis, Minnesota 55455, United States
  • The Children's Hospital of Philadelphia (CHOP)
    Philadelphia, Pennsylvania 19104, United States
  • UPMC Children's Hospital of Pittsburgh
    Pittsburgh, Pennsylvania 15224, United States
  • The Hospital for Sick Children
    Toronto, Ontario M5G 1X8, Canada
  • McGill University Health Centre - The Montréal Children's Hospital
    Montreal, Quebec H4A 3J1, Canada
  • HCL - Hôpital Mère Enfant
    Bron, 69677, France
  • CHU Strasbourg - Hopital Hautepierre
    Strasbourg, 67200, France
  • Universitätsklinikum Würzburg
    Würzburg, Bavaria 97080, Germany
  • Ambulantes Operieren Marburg
    Marburg, Hesse 35039, Germany
  • Universitaetsklinikum Giessen und Marburg GmbH
    Marburg, Hesse 35043, Germany
  • Universitaetsklinikum Bonn - Klinik für Anaesthesiologie & Operative Intensivmedizin
    Bonn, North Rhine-Westphalia 53127, Germany
  • Helios Klinikum Aue
    Aue, 08280, Germany
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2024 to primary completion in Jun 2025, 16 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 12, 2022
First posted
Sep 19, 2022
StartActual
Jan 18, 2024
Primary completionActual
Jun 3, 2025
CompletionActual
Jun 3, 2025
Last update
Jun 25, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 25, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05546359
Lead sponsor
Acacia Pharma Ltd
Collaborators
Amicus CD LLC, Premier Research
Responsible party
Sponsor
First posted
Sep 19, 2022
Start date
Jan 18, 2024
Primary completion
Jun 3, 2025
Completion
Jun 3, 2025
Last update
Jun 25, 2025

Study contacts

Kumar Belani, MD
principal investigator · University of Minnesota Masonic Children's Hospital

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Amisulpride

Start the discussion